Masateru Kohno Selected Research

K201 compound

3/2003	A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure.
1/2003	FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masateru Kohno Research Topics

Disease

5	Heart Failure 01/2020 - 03/2002
1	Malignant Hyperthermia 01/2020
1	Cardiac Arrhythmias (Arrythmia) 01/2020
1	Ventricular Fibrillation 01/2020
1	Ventricular Tachycardia 01/2020
1	Tachycardia (Tachyarrhythmias) 03/2003
1	Hyperplasia 05/2002
1	Congenital Abnormalities (Deformity) 05/2002
1	Ventricular Remodeling 03/2002

Drug/Important Bio-Agent (IBA)

4	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 01/2020 - 03/2002
3	tacrolimus binding protein 1BIBA 03/2003 - 03/2002
2	K201 compoundIBA 03/2003 - 01/2003
1	Dantrolene (Dantrium)FDA LinkGeneric 01/2020
1	Pharmaceutical PreparationsIBA 01/2020
1	Protein Isoforms (Isoforms)IBA 01/2020
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 02/2004
1	Angiotensin Receptor AntagonistsIBA 02/2004
1	Valsartan (Vals)FDA Link 02/2004
1	Cardiotonic Agents (Cardiac Stimulants)IBA 03/2003
1	CalciumIBA 01/2003
1	Propranolol (Inderal)FDA LinkGeneric 03/2002
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 03/2002

Therapy/Procedure

1	Stents 05/2002